Kintara Therapeutics (KTRA) is Suspending Development of VAL-08

Go back to Kintara Therapeutics (KTRA) is Suspending Development of VAL-08

Kintara Therapeutics Announces Preliminary Topline Results From GBM AGILE Study

October 31, 2023 8:00 AM EDT

- VAL-083 Did Not Perform Better Than Current Standards of Care -

- Company Suspending Development of VAL-083, Shifting Focus to REM-001 Program and Other Strategic Opportunities -

SAN DIEGO, Oct. 31, 2023 /PRNewswire/ --... More